Apellis Pharmaceuticals Inc. News
Cramer's Mad Money Recap 10/6: Dow, General Motors
Jim Cramer says it's hard to explain why stocks opened lower, but he thinks investors should have some conviction and look for buying opportunities.
5 Top Stock Gainers for Monday: Discovery, Apellis Pharma
Apellis Pharmaceuticals, Harley-Davidson, Dillard's, Children's Place and Harmony Gold are five top gainers for Monday.
Apellis Jumps on Blood Disease Treatment Approval
Apellis says the U.S. Food & Drug Administration has approved its Empaveli treatment for a rare blood disease.
Editas Medicine Falls as Goldman Sachs Initiates the Stock at Sell
Editas is initiated with a sell rating and $20 price target at Goldman Sachs.
Resilient Bull: Cramer's 'Mad Money' Recap (Wednesday 1/8/20)
Jim Cramer says this market environment is a strange merger of resilience, complacency and hubris. He explains how this feeds a stock rally.
Apellis Pharmaceuticals Soars on Blood-Drug Test
Apellis' treatment for PNH, a rare blood disease, outperforms Alexion's Soliris, the company says.
Apellis Pharma Climbs on Upgrade to Overweight at JP Morgan
JP Morgan analysts see promising opportunities in Apellis's later-stage drug to treat the blood disorder PNH.
Breaking News
The Arena Group Q2 Gross Profit Nearly Doubles; Revenue Up 87%
The Arena Group, publisher of Sports Illustrated, TheStreet, Parade and more, reported that Q2 gross profit, revenue and digital-ad revenue jumped.
Will JetBlue Take Away the One Thing People Like About Spirit?
The takeover of the budget airline raises a key question for consumers.
Micron and Nvidia: Buy or Sell After Bearish Updates?
Nvidia provided negative news on Monday and Micron followed up with more on Tuesday. Here's the trade.
Walmart Builds on Its Biggest Edge Over Amazon
Retailing giant Walmart wants to ensure its customers can get what they're looking for, however they want to buy it.